Global Kirsten Rat Sarcoma Kras Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 3.69 Billion |
 Market Size (Forecast Year) |
USD 3.37 Billion |
 CAGR |
% |
| Major Markets Players |
全球克尔斯滕大鼠肉瘤 (KRAS) 市场，按癌症类型（乳腺癌、胰腺癌、结肠癌、肺癌等）、应用（开发和药物配方、分子诊断开发、疾病诊断、药物发现和开发、个性化医疗、预测、预后、研究和开发、风险评估、治疗）最终用户（学术和癌症研究机构、门诊手术中心、癌症诊断中心和研究实验室、临床实验室、合同研究组织 (CRO)、医疗 IT/大数据公司、医院、制药和生物技术公司）– 行业趋势和预测到 2029 年
市场分析和规模
新近重新编程的代谢途径和致癌代谢物会影响致瘤环境。开发调节胰腺癌细胞代谢重编程的方法可以为新的治疗策略铺平道路。提供乙酰辅酶 A 和 NADPH 的主要代谢途径是胰腺癌细胞脂质合成和细胞增殖所必需的。
Data Bridge Market Research 分析，2021 年 kirsten 大鼠肉瘤 (KRAS) 市场规模为 9000 万美元，到 2029 年将飙升至 1.2508 亿美元，预计在 2022 年至 2029 年的预测期内复合年增长率为 4.20%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
报告范围和市场细分
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制为 2014 - 2019） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
癌症类型（乳腺癌、胰腺癌、结肠癌、肺癌、其他）、应用（开发和药物配方、分子诊断开发、疾病诊断、药物发现和开发、个性化医疗、预测、预后、研究和开发、风险评估、治疗）最终用户（学术和癌症研究机构、门诊手术中心、癌症诊断中心和研究实验室、临床实验室、合同研究组织（CRO）、医疗 IT/大数据公司、医院、制药和生物技术公司） |
|
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd (Switzerland), Qiagen (Germany), Agilent Technologies Inc. (U.S), Illumina Inc. (U.S), Thermo Fisher Scientific Inc. (U.S), Abbott (U.S), NimaGen BV (Netherlands), Agena Bioscience Inc. (China), BML Inc. (Japan), Takara Bio Inc. (Japan), New England Biolabs (U.S), Amoy Diagnostics Co Ltd (Japan), Panagene (South Korea), EntroGen (U.S), Sysmex Corporation (Japan), Biocartis (Belgium) |
|
Market Opportunities |
|
Market Definition
Kirsten rat sarcoma viral oncogene homolog (KRAS)-driven pancreatic cancer is extremely fatal, with a five-year survival rate of only 9%. Because of the specificities of pancreatic tumors, several treatment techniques such as chemotherapy, radiation, and immunotherapy showed very moderate efficacy. Surgery is the primary curative option in the early stages of the disease, however only in 20% of individuals with early stage disease.
Kirsten Rat Sarcoma (KRAS) Market Dynamics
Drivers
- Innovative development in the pharmaceuticals
The kirsten rat sarcoma (KRAS) market is widely supported by the accelerating trend of in vitro diagnostics and ongoing research in its treatment section. The need for Kirsten rat sarcoma has grown as the number of people diagnosed with lung cancer has increased (KRAS). The kirsten rat sarcoma (KRAS) market is expanding because of innovative pharmaceutical development and the production of new medications to battle various tumors. These factors are projected to fuel market expansion in the forecasted time range of 2022 to 2029.
- Rising demand for targeted therapies
According to the results of the analysis, the global KRAS inhibitor market is expected to exceed USD 4.5 billion by 2028, owing to rising demand for targeted medicines and increasing acceptance in cancer management. The research provides in-depth analysis of the pipeline therapeutics landscape and growth prospects for KRAS Inhibitor development. The paper covers the pipeline environment for this mechanism of action in depth and commercial information on already marketed KRAS inhibitors.
- Novel drugs and inhibitors
Lumakras has exhibited high acceptance rates in the market since its introduction, with global sales of around USD 90 million in 2021. The positive response to the innovative medicine has prompted more research and development efforts in this area. Adagrasib, JQ443, GDC-6036, BI 1823911, JNJ-74699157, MK-1084, and others are among the many possible KRAS inhibitors in development. Adagrasib is one of the most advanced KRAS inhibitors currently in phase-III clinical trials, whereas the others are mostly in phase-I/II trials.
Opportunities
Biomarker testing, which informs therapy options during disease, is an unmet need with improvements in precision medicine. After receiving US regulatory approval as a companion diagnostic to aid in the identification of non-small cell lung cancer (NSCLC) patients who may be eligible for treatment with Lumakras, Qiagen 2021 announced the launch of an expanded scope of companion diagnostic (CDx) claims for the therascreen KRAS RCQ PCR kit (therascreen KRAS Kit). The diagnostic test will be marketed in the United States in collaboration with Labcorp.
Restraints/Challenges
Some restrictions, such as a lack of understanding regarding the benefits of Kirsten rat sarcoma (KRAS) research, may limit market expansion. Clinical and laboratory diagnostics demand high-cost funding. Major studies are still in the works. These factors may hinder the market growth.
This kirsten rat sarcoma (KRAS) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the kirsten rat sarcoma (KRAS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In January 2021, For Advanced Comprehensive Genomic Profiling, Illumina, Inc. established partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck. The collaborations will help the organisation achieve its goal of developing standardised precision oncology tools. It would result in good market growth.
- In October 2020, Thermo Fisher Scientific Inc. announced that it would extend its relationship with Symphogen in order to provide breakthrough cancer treatments by optimising protein characterization and quality monitoring mass spectrometry procedures. To improve drug delivery, the companies can provide compliance-ready mass spectrometer solutions to the biopharmaceutical industry. It would result in good market growth.
Global Kirsten Rat Sarcoma (KRAS) Market Scope
克氏大鼠肉瘤 (KRAS) 市场根据类型、应用和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
类型
- 乳腺癌
- 胰腺癌
- 结肠癌
- 肺癌
- 其他的
应用
- 开发和药物配方
- 分子诊断的发展
- 疾病诊断
- 药物研发
- 个性化医疗
- 预测
- 预测
- 研究与开发
- 风险评估
- 治疗
终端用户
- 学术和癌症研究机构
- 门诊手术中心
- 癌症诊断中心和研究实验室
- 诊所实验室
- 合同研究组织（CRO）
- 医疗 IT/大数据公司
- 医院
- 制药和生物技术公司
克尔斯滕大鼠肉瘤 (KRAS)市场区域分析/见解
对 kirsten 大鼠肉瘤 (KRAS) 市场进行了分析，并按国家、类型、应用和最终用户提供了市场规模洞察和趋势，如上所述。
克尔斯滕大鼠肉瘤（KRAS）市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
由于与 kirsten 大鼠肉瘤 (KRAS) 突变相关的癌症发病率不断上升且研发支出增加，北美预计将主导 kirsten 大鼠肉瘤 (KRAS) 市场。
由于 kirsten 大鼠肉瘤 (KRAS) 突变的患病率高以及创新产品的渗透性，美国在北美 kirsten 大鼠肉瘤 (KRAS) 试剂和试剂盒市场中占据主导地位。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和克尔斯滕大鼠肉瘤 (KRAS) 市场份额分析
克尔斯滕大鼠肉瘤 (KRAS) 市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对克尔斯滕大鼠肉瘤 (KRAS) 市场的关注有关。
在克尔斯滕大鼠肉瘤 (KRAS) 市场运营的一些主要参与者包括：
- F. Hoffmann-La Roche Ltd（瑞士）
- Qiagen (德国)
- 安捷伦科技公司（美国）
- Illumina Inc.（美国）
- 赛默飞世尔科技公司（美国）
- 雅培（美国）
- NimaGen BV（荷兰）
- Agena Bioscience Inc. (中国)
- BML Inc.（日本）
- Takara Bio Inc.（日本）
- 新英格兰生物实验室（美国）
- 厦门诊断有限公司 (日本)
- Panagene（韩国）
- EntroGen (美国)
- Sysmex 公司 (日本)
- Biocartis（比利时）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
